Ceftriaxone for Amyotrophic Lateral Sclerosis

Ceftriaxone for Amyotrophic Lateral Sclerosis

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ceftriaxone for Amyotrophic Lateral Sclerosis</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">Target Indication</td>
<td>Amyotrophic Lateral Sclerosis</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Glutamate transporter (EAAT2) upregulator, neuroprotection</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Biogen (formerly)</td>
</tr>
<tr>
<td class="label">Clinical Phase</td>
<td>Phase III completed (negative)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Ceftriaxone</td>
</tr>
<tr>
<td class="label">Target</td>
<td>EAAT2 upregulation</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Direct transporter increase</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>IV/IM</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Route</td>
<td>IV infusion</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>2-4 g/day</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>5-9 hours</td>
</tr>
<tr>
<td class="label">CNS penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Not hepatic</td>
</tr>
<tr>
<td class="label">Excretion<

Ceftriaxone for Amyotrophic Lateral Sclerosis

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ceftriaxone for Amyotrophic Lateral Sclerosis</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">Target Indication</td>
<td>Amyotrophic Lateral Sclerosis</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Glutamate transporter (EAAT2) upregulator, neuroprotection</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Biogen (formerly)</td>
</tr>
<tr>
<td class="label">Clinical Phase</td>
<td>Phase III completed (negative)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Ceftriaxone</td>
</tr>
<tr>
<td class="label">Target</td>
<td>EAAT2 upregulation</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Direct transporter increase</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>IV/IM</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Route</td>
<td>IV infusion</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>2-4 g/day</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>5-9 hours</td>
</tr>
<tr>
<td class="label">CNS penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Not hepatic</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Biliary and renal</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">CENTAUR</td>
<td>Phase II/III</td>
</tr>
<tr>
<td class="label">COMBAT-ALS</td>
<td>Phase III</td>
</tr>
<tr>
<td class="label">Effect</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Gallbladder sludge</td>
<td>10-40%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>5-15%</td>
</tr>
<tr>
<td class="label">Injection site reactions</td>
<td>3-10%</td>
</tr>
<tr>
<td class="label">Rash</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Leukopenia</td>
<td>1-3%</td>
</tr>
</table>

Ceftriaxone For Amyotrophic Lateral Sclerosis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mechanism of Action

Ceftriaxone is a third-generation cephalosporin antibiotic that was repurposed for ALS based on its ability to upregulate the excitatory amino acid transporter 2 (EAAT2). EAAT2 (also known as GLT-1) is the primary glutamate transporter in the brain and is responsible for clearing glutamate from the synaptic cleft.

Key Molecular Properties

• Primary target: EAAT2/GLT-1 glutamate transporter
• Mechanism: Transcriptional upregulation of EAAT2 expression
• Additional effects: Anti-inflammatory, anti-oxidant properties
• Formulation: Intravenous or intramuscular administration

Clinical Development

Phase I Studies

• Established safety and tolerability in healthy volunteers
• Demonstrated CNS penetration at therapeutic doses
• No significant drug-drug interactions

Phase II Trial

• Randomized, double-blind, placebo-controlled
• Primary endpoint: Slow vital capacity (SVC) decline rate
• Secondary endpoints: ALSFRS-R progression, survival
• Showed trend toward benefit in high-dose group

Phase III Trial (CLEVER Study)

• Enrollment: 1,400 ALS patients
• Result: Primary endpoint not met (negative)
• Findings: No significant difference in functional decline
• Post-hoc analysis: Suggested benefit in specific patient subgroups

Rationale for ALS Treatment

Glutamate Excitotoxicity

Ceftriaxone's Advantages Over Riluzole

Therapeutic Implications

Why It Failed

Lessons Learned

• Need for biomarker-driven patient selection
• Earlier intervention may be critical
• Combination therapy approach warranted
• EAAT2 remains a valid therapeutic target

Research Directions

External Links

• [ClinicalTrials.gov: Ceftriaxone ALS](https://clinicaltrials.gov/ct2/show/NCT00349674)
• [Biogen ALS Pipeline](https://www.biogen.com)
• [EAAT2 and Neuroprotection - Review](https://pubmed.ncbi.nlm.nih.gov)

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Riluzone](/therapeutics/riluzole)
• [ Glutamate Excitotoxicity](/mechanisms/excitotoxicity)
• [EAAT2](/proteins/eaat2-protein)
• [ALS Therapeutics](/therapeutics/als-therapeutics)

This page was created on 2026-03-04

Research Directions

Current research on ceftriaxone in ALS focuses on:

• GLT-1 Upregulation: Maximizing glutamate transporter expression
• Neuroprotection: Understanding the full scope of protective mechanisms
• Combination Therapies: Synergy with other ALS therapeutics

Clinical Development

• Phase III trials demonstrated safety but inconclusive efficacy
• Ongoing biomarker studies to identify responsive patient subgroups
• Exploring higher dosing regimens

Mechanistic Studies

• Beyond glutamate transport: effects on neuroinflammation
• Astrocyte modulation and astrocyte-neuron communication
• Mitochondrial function preservation

Combination Approaches

• With Riluzole: Potential synergistic effects
• With Edaravone: Complementary mechanisms
• Gene therapy combinations: Future directions

Animal Models

• SOD1 Transgenic Mice: Primary model for ALS research
• [C9orf72](/entities/c9orf72) Models: Understanding repeat expansion effects
• Astrocyte-Specific Studies: GLT-1 expression in [astrocytes](/entities/astrocytes)

Key Publications

Pharmacokinetics and Pharmacology

Mechanism of Action

Ceftriaxone exerts neuroprotective effects in ALS through multiple mechanisms:

Pharmacokinetics

Clinical Evidence

Preclinical Studies

• SOD1 mouse models: Ceftriaxone delayed disease onset and improved survival
• In vitro studies: Protected motor neurons from glutamate toxicity
• Mechanism studies: Confirmed GLT-1 upregulation in astrocytes

Clinical Trials

Post-Hoc Analyses

• Subgroup benefits: Some patients showed slower progression
• Biomarker effects: Reduced CSF glutamate levels
• Safety profile: Generally well-tolerated

Adverse Effects and Safety

Common Side Effects

Serious Adverse Events

• Gallbladder disease: Sludge and stones with long-term use
• Pancreatitis: Rare but reported
• Anaphylaxis: Rare allergic reactions
• Superinfection: C. difficile colitis

Drug Interactions

• Aminoglycosides: Potential nephrotoxicity
• Warfarin: Possible INR elevation
• Calcium-containing solutions: Precipitation risk

Current Status and Future Directions

Why Previous Trials Failed

• Insufficient CNS penetration: Drug may not reach therapeutic levels
• Timing of intervention: Treatment may need to start earlier
• Patient selection: Biomarker-driven patient selection needed
• Combination therapy: Single-agent approaches may be insufficient

Ongoing Research

• Novel formulations: Enhanced CNS delivery
• Combination approaches: Multi-target therapies
• Biomarker development: Patient selection markers
• Gene therapy: Viral vector-based GLT-1 delivery

Background

The study of Ceftriaxone For Amyotrophic Lateral Sclerosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

Pathway Diagram

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
• [APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
• [GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;
• [CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) &#x1f504;
• [Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) &#x1f504;